StockNews.AI
TNYA
StockNews.AI
153 days

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

1. New data on TN-201 will be presented at ACC session. 2. TN-201 is a gene therapy for MYBPC3-associated HCM. 3. Results include assessments from early trial patients. 4. Differences in disease burden for MYBPC3 mutations will be showcased. 5. Presentations could signal advancements in heart disease therapies.

6m saved
Insight
Article

FAQ

Why Bullish?

Upcoming data presentation could enhance investor confidence, similar to prior encouraging updates.

How important is it?

The presentation may lead to technical validation and investor interest in TNYA.

Why Short Term?

The impact is likely immediate given the ACC presentation, stimulating market interest.

Related Companies

REGNEDITCRIS
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 March 19, 2025 08:30 ET  | Source: Tenaya Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that new clinical and disease burden data pertaining to the company’s MYBPC3-associated hypertrophic cardiomyopathy (HCM) program will be presented at the upcoming American College of Cardiology’s Annual Scientific Session being held March 29-31, 2025 in Chicago, IL. Tenaya is advancing TN-201, an AAV9-based gene therapy for the potential treatment of MYBPC3-associated HCM, a condition caused by insufficient levels of myosin-binding protein C (MyBP-C). As part of the late-breaking Clinical and Investigative Horizons session on Monday, March 31, data from the first cohort of adult patients enrolled in the MyPEAK-1 Phase 1b/2 clinical trial will be featured. Building on early encouraging data shared in December 2024, the presentation at ACC will include results from one-year assessments of the first two patients to receive TN-201 gene therapy, and baseline biopsy and six-month assessments from the third patient in the 3E13 vg/kg cohort. These data will be presented by Milind Desai, M.D., M.B.A, Haslam Family Endowed Chair in Cardiovascular Medicine, Vice Chair, Heart Vascular Thoracic Institute, Director of the Hypertrophic Cardiomyopathy Center at the Cleveland Clinic, and an investigator for the MyPEAK-1 Phase 1b/2 clinical trial. A poster presentation on Sunday, March 30, will detail findings from SHaRe (Sarcomeric Human Cardiomyopathy Registry), describing differences in disease burden among adults with HCM caused by MYBPC3 mutations. Details of the presentations are as follows: Sunday, March 30, 2025 Poster: Differences in Patient Characteristics and Burden of Disease in Adults with MYBPC3-Associated HCM (#129)Presenting author: Whit Tingley, M.D., Ph.D., Tenaya TherapeuticsSession 1152: Heart Failure and CardiomyopathiesTime and location: 10:30 am – 11:30 am CT; South Hall Monday, March 31, 2025 - ACC Late-breaking presentation Presentation: First Report of Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201, an Adeno-Associated Virus Serotype 9 Gene Replacement Therapy, in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy (abstract ##)Presenting author: Dr. Milind Desai, M.D., M.B.A., Cleveland ClinicSession 402: Heart Failure and CardiomyopathiesTime and location: 9:00 am – 10:00 am CT; S100B To view full event programming, please visit the ACC.25 website. Following the conference, Tenaya’s presentations will be available in the “Our Science” section of the company’s website. About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging integrated proprietary core capabilities enabling target identification and validation, design of AAV-based genetic medicines and in-house manufacturing the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com. Contact Michelle CorralVP, Corporate Communications and Investor RelationsTenaya TherapeuticsIR@TenayaThera.com InvestorsAnneMarie FieldsStern IR AnneMarie.Fields@SternIR.com MediaWendy RyanTen Bridge Communicationswendy@tenbridgecommunications.com

Related News